<DOC>
	<DOCNO>NCT00991562</DOCNO>
	<brief_summary>The purpose study test IMGN901 combination lenalidomide dexamethasone every 28 day .</brief_summary>
	<brief_title>IMGN901 Combination With Lenalidomide Dexamethasone</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Diagnosis multiple myeloma base standard criterion . Patients must CD56positive , relapsed relapsed/refractory multiple myeloma . Myeloma consider CD56positive either immunohistochemistry ( IHC ) flow cytometry criterion define Appendix X meet . Age &lt; 18 year time signing Informed Consent . Patients Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . During dose escalation phase , patient must receive least one prior therapy multiple myeloma . The prior therapy therapy include lenalidomide treatment . Once MTD/RPTD define , patient receive least 1 3 prior chemotherapy regimen enrol dose level study . Prior regimen ( ) may include bortezomib bortezomib component . If prior regimen ( ) include lenalidomide component : Patients last dose lenalidomide must ≥ 6 month Day 1 treatment BB10901 ( exception maintenance lenalidomide treatment complete least 4 week prior Day 1 treatment BB10901 ) , Patients must achieve response stable disease well lenalidomide treatment , Patients must discontinue treatment due lenalidomide intolerance . Patients must able adhere study visit schedule protocol requirement . Patients must understand voluntarily sign informed consent document . Woman child bear potential ( WCBP ) must negative pregnancy test within 10 14 day within 24 hour prior write initial prescription lenalidomide even continuous abstinence choose method birth control . In addition , sexually active WCBP must agree frequent pregnancy test outline protocol must agree use 2 contraceptive method . WCBP must agree follow requirement least 4 week begin treatment lenalidomide least 4 week last treatment lenalidomide . Male patient must agree use latex condom even successful vasectomy male donate sperm . Males must agree follow requirement least 4 week follow last dose study drug . Patients may receive chemotherapy widefield radiotherapy ( e.g . .30 % marrowbearing bone ) complete least 4 week prior Day 1 , focal radiation complete least 2 week prior Day 1 , patient recover stabilized adverse effect therapy . Therapy nitrosoureas mitomycin C must complete 6 week prior Day 1 . Major surgery ( include placement vascular access device tumor biopsy ) must complete 4 week prior Day 1 . Antineoplastic therapy biological agent must complete least 2 week prior Day 1 . Absolute neutrophil count ( ANC ) ≥ 1000 cells/mm3 , hemoglobin ≥ 8.5 g/dL , platelet count ≥ 50,000/mm3 Aspartate aminotransferase ( AST ) ( serum glutamic oxalacetic transaminase , SGOT ) alanine aminotransferase ( ALT ) ( serum glutamic pyruvate transaminase , SGPT ) ≤ 3 x upper limit normal ( ULN ) total bilirubin ≤ 1.5 x ULN Amylase lipase level must ≤ 1.5 x ULN . Serum Creatinine ≤ 1.5 x ULN Left ventricular ejection fraction ≥ low limit normal ( LLN ) MUGA scan ECHO . Patients must agree follow guideline RevAssist® Program Concomitant therapy antineoplastic treatment ( chemotherapy , radiotherapy biological agent ) study . Peripheral neuropathy grade 2 great . Known hypersensitivity lenalidomide thalidomide derivative , previous monoclonal antibody therapy maytansinoids . History deep venous thrombus pulmonary embolism within 6 month study enrollment . Any serious medical condition , laboratory abnormality , psychiatric disorder , opinion Investigator place patient unacceptable risk he/she participate study . Clinically relevant active infection include active hepatitis B C , Human Immunodeficiency Virus ( HIV ) infection , concurrent disease , judgment Investigator , would make patient inappropriate enrollment study . Significant cardiac disease recent myocardial infarction ( ≤ 6 month prior Day 1 ) , unstable angina , uncontrolled congestive heart failure , uncontrolled hypertension ( recurrent persistent increase systolic blood pressure ≥ 180 mmHg diastolic blood pressure ≥ 110 mmHg ) , uncontrolled cardiac arrhythmia , grade 3 great cardiac toxicity follow prior chemotherapy . History multiple sclerosis demyelinate disease , EatonLambert syndrome ( paraneoplastic syndrome ) , history hemorrhagic ischemic stroke within last 6 month , central nervous system ( CNS ) injury residual neurological deficit , alcoholic liver disease . Treatment another investigational agent study ≤ 4 week prior Day 1 . Prior malignancy within last 3 year except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , situ breast cancer , situ prostate cancer . Patients know recent biochemical clinical evidence pancreatitis extensive metastatic disease involve pancreas associate increased amylase and/or lipase exclude . ( Note : Enrollment patient metastatic disease , around , pancreas may allow agreement Sponsor Investigator ) . WCBP pregnant breast feed men woman use adequate contraception exclude . Patients unwilling unable comply requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>relapsed relapsed/refractory multiple myeloma</keyword>
</DOC>